SEC Form 4 · accession 0001209191-18-026574
Evoke Pharma Inc · EVOK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott L Glenn
Director
Period of report
Apr 26, 2018
Accepted (ET)
Apr 27, 2018 · 4:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001403708
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.36 | Apr 26, 2018 | A | 32,500 | A | — | Apr 25, 2028 | Common Stock | 32,500 | 32,500 | D |
Explanation of responses
- F1The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant (4/26/2019), subject to the reporting person's continued service to the Issuer through such vesting date.